Lapatinib plus Capecitabine for Brain Metastases in Patients with Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Review of the Anatolian Society of Medical Oncology (ASMO) Experience

Publisher： Karger

E-ISSN： 2296-5262|35|12|740-745

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.35, Iss.12, 2012-10, pp. : 740-745

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Brain Metastases of Her2-Positive Breast Cancer: A Case of 34 Months' Remission with Lapatinib plus Capecitabine

By  

Case Reports in Oncology, Vol. 7, Iss. 2, 2014-08 ,pp. : 555-559

Karger

Access to resources Recommend Favorite

Patient‐reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer

By  

CANCER, Vol. 120, Iss. 5, 2014-03 ,pp. : 642-651

John Wiley & Sons Inc

Access to resources Recommend Favorite

Biological Subtypes and Survival Outcomes in Breast Cancer Patients with Brain Metastases (Study of the Anatolian Society of Medical Oncology)

By  

Oncology, Vol. 83, Iss. 3, 2012-07 ,pp. : 141-150

Karger

Access to resources Recommend Favorite

Impact of clinicopathological characteristics on the efficacy of neoadjuvant therapy in patients with human epidermal growth factor receptor‐2‐positive breast cancer

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 142, Iss. 4, 2018-02 ,pp. : 844-853

John Wiley & Sons Inc

Access to resources Recommend Favorite

Hormonal Receptor, Human Epidermal Growth Factor Receptor-2, and Ki67 Discordance between Primary Breast Cancer and Paired Metastases: Clinical Impact

By  

Oncology, Vol. 84, Iss. 3, 2012-12 ,pp. : 150-157

Karger

Access to resources Recommend Favorite